全球再生醫學膠原蛋白和明膠市場規模（按來源、應用、地區、範圍和預測）

再生醫學用膠原蛋白及明膠的市場規模及預測

再生醫學的膠原蛋白和明膠市場預計在 2024 年達到 9.5428 億美元，在 2031 年達到 16.2613 億美元，2024 年至 2031 年的複合年增長率為 7.6%。膠原蛋白是人體內最常見的蛋白質，存在於皮膚、關節和骨骼等結締組織中，提供結構和穩定性。明膠是部分水解且三螺旋結構變性的膠原蛋白。膠原蛋白和明膠因其生物相容性、細胞識別位點和可調節的生物降解性而被應用於再生醫學，從而推動了組織工程、細胞治療和增強藥物傳遞方面的突破性進展。

此外，膠原支架可促進細胞發育和沈積，但由於明膠的獨特性質，可以對其進行改性以改善其生物和功能特性，從而支持組織再生。

再生醫學用膠原蛋白和明膠的全球市場動態

主要市場驅動因子

慢性病和傷害盛行率不斷上升：

需要組織修復和再生的慢性疾病和損傷的日益流行是再生醫學市場膠原蛋白和明膠的主要驅動力。根據世界衛生組織（WHO）的數據，慢性病佔全球所有死亡人數的71%，即每年4,100萬人。根據美國疾病管制與預防中心(CDC) 的數據，大約四分之一(26%) 的美國成年人患有某種類型的殘疾，其中許多人可以從使用膠原蛋白和明膠的再生醫學治療中受益。

老年人口不斷增加：

全球人口老化正在推動對再生醫學用膠原蛋白和明膠解決方案的需求。根據聯合國《2019年世界人口前景》報告，到2050年，每六人中就有一人年齡超過65歲（16%），高於每十一個人中就有一人（9%）。這種人口結構變化導致與年齡相關的疾病（如骨關節炎）的發生率上升，根據美國疾病管制與預防中心統計，僅在美國就有約 3,250 萬人患有骨關節炎。膠原蛋白和明膠類藥物在解決這些與年齡相關的問題的潛力正在推動市場擴張。

組織工程與再生醫學研究的進展：

組織工程和再生醫學的持續研究和開發正在推動膠原蛋白和明膠市場向前發展。美國國立衛生研究院（NIH）報告稱，2020財政年度將在再生醫學研究方面投資約25億美元。此外，再生醫學聯盟報告稱，截至 2020 年底，全球共有 1,220 項再生醫學和先進療法臨床試驗正在進行，其中許多涉及基於膠原蛋白和明膠的技術。

主要問題

替代生物材料的可用性：

殼聚醣、海藻酸鹽和透明質酸等替代生物材料的出現對膠原蛋白和明膠市場構成了重大課題。這些替代材料具有類似甚至更好的癒合和再生特性，推動了製造商和醫療保健專業人員的選擇轉變。隨著這些替代品越來越受歡迎，它們限制了膠原蛋白和明膠基產品在再生應用領域的成長潛力，嚴重影響了市場動態。

批次差異與品質控制問題：

膠原蛋白和明膠產品批次間存在差異，產生一致性和品質問題。這種不可預測性使製造過程變得複雜，並降低了這些生物材料在治療環境中的可靠性。此外，淨化和品質控制的困難阻礙了研究人員和臨床醫生充分採用這些產品，限制了它們在再生醫學中的廣泛應用。

主要趨勢：

對植物性、永續來源的需求不斷增加：

出於道德和環境方面的考慮，消費者越來越青睞植物性、可持續的膠原蛋白和明膠來源。這就導致了從海藻、米蛋白和豌豆蛋白中提取的新替代品的出現。各公司正在投資研究，開發更有效率、更環保的生產工藝，以滿足再生醫學應用對植物替代品日益增長的需求。

在高階傷口護理和組織工程中的應用日益廣泛：

膠原蛋白和明膠由於其高度的生物相容性、生物降解性和促進細胞發育和組織再生的能力，越來越多地被用於先進的傷口護理和組織工程。該公司投資研發，開發用於傷口癒合、骨再生和器官替代的創新膠原蛋白和明膠解決方案。慢性傷口、糖尿病和癌症的發生率不斷上升，推動了對這些先進再生醫學解決方案的需求。

目錄

第 1 章。

市場概況
• 研究範圍
• 先決條件

第 2 章執行摘要

第 3 章：經過驗證的市場研究方法

• 資料探勘
• 驗證
• 主要來源
• 資料來源列表

第 4 章。

• 概述
• 市場動態
  • 驅動程式
  • 阻礙因素
  • 機會
• 波特五力模型
• 價值鏈分析
• 監理框架

第 5 章。

• 膠原蛋白原料
  • 牛
  • 豬
  • 海洋
• 明膠原料
  • 牛
  • 豬
  • 其他

6. 全球再生醫學膠原蛋白及明膠市場（依應用）

• 膠原蛋白
  • 骨科
  • 傷口護理
  • 循環系統
  • 其他
• 明膠
  • 傷口護理
  • 骨科
  • 循環系統
  • 其他

7. 全球再生醫學膠原蛋白和明膠市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
  亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區
  • 拉丁美洲
  • 中東和非洲

8. 全球再生醫學膠原蛋白與明膠市場：競爭格局

• 概述
• 公司市佔率
• 供應商概況
• 主要發展策略

第九章 公司簡介

• Integra Lifesciences Holdings Corporation
• Collagen Matrix, Inc.
• Collagen Solutions PLC
• Royal DSM
• VorniaBiomaterials Ltd.
• Symatese
• Nucollagen LLC.
• Gelita AG
• Nitta Gelatin Inc.
• PB Gelatin

第 10 章附錄

• 相關研究

Collagen and Gelatin Market for Regenerative Medicine Market Size and Forecast

Collagen and Gelatin Market for Regenerative Medicine Market size was valued at USD 954.28 Million in 2024 and is projected to reach USD 1626.13 Million by 2031, growing at a CAGR of 7.6% from 2024 to 2031. Collagen is the body's most prevalent protein, found in connective tissues such as skin, joints, and bones, where it provides structure and stability. Gelatin is a deteriorated form of collagen that results from partial hydrolysis, which denatures the triple helical structure. Collagen and gelatin are employed in regenerative medicine due to their biocompatibility, cell recognition sites, and tunable biodegradability, which enable breakthroughs in tissue engineering, cellular treatment, and enhanced drug administration.

Furthermore, collagen scaffolds promote cell development and deposition, but gelatin's unique features allow it to be changed to improve its biological and functional qualities, opening up new avenues for biomaterials that can support tissue regeneration.

Global Collagen and Gelatin Market for Regenerative Medicine Market Dynamics

The key market dynamics that are shaping the collagen and gelatin market for regenerative medicine market include:

Key Market Drivers

Increasing Prevalence of Chronic Diseases and Injuries:

The increasing prevalence of chronic diseases and injuries necessitating tissue repair and regeneration is a major driver of the collagen and gelatin market for regenerative medicine. According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths worldwide, or 41 million people per year. According to the Centers for Disease Control and Prevention (CDC), approximately one in every four adults (26%) in the United States suffers from some form of impairment, many of which could benefit from regenerative medicine treatments utilizing collagen and gelatin.

Growing Aging Population:

The worldwide aging population is boosting demand for regenerative medicine solutions based on collagen and gelatin. According to the United Nations World Population Prospects 2019 report, by 2050, one in every six individuals will be beyond the age of 65 (16%), up from one in every eleven (9%). This demographic change is driving up the prevalence of age-related illnesses like osteoarthritis, which affects an estimated 32.5 million individuals in the United States alone, according to the CDC. The potential for collagen and gelatin-based medicines to address these age-related problems is driving market expansion.

Advancements in Tissue Engineering and Regenerative Medicine Research:

Continuous research and development in tissue engineering and regenerative medicine are driving the collagen and gelatin market forward. The National Institutes of Health (NIH) reports that it invested around USD 2.5 Billion in regenerative medicine research in fiscal year 2020. Also, the Alliance for Regenerative Medicine reports that 1,220 clinical trials in regenerative medicine and advanced therapies will be underway worldwide by the end of 2020, with many of them involving collagen and gelatin-based techniques.

Key Challenges:

Availability of Alternative Biomaterials:

The emergence of replacement biomaterials such as chitosan, alginate, and hyaluronic acid presents a substantial challenge to the collagen and gelatin market. These alternatives offer equivalent or superior healing and regeneration qualities, prompting a shift in choice among manufacturers and healthcare professionals. As these replacements acquire popularity, they limit the growth potential of collagen and gelatin-based products in regenerative applications, severely affecting market dynamics.

Batch Variability and Quality Control Issues:

Collagen and gelatin products have batch-to-batch variability, raising issues about uniformity and quality. This unpredictability complicates the manufacturing process and reduces the dependability of these biomaterials in therapeutic settings. Furthermore, difficulties with purification and quality control prevent researchers and clinicians from completely adopting these products, restricting their widespread use in regenerative medicine.

Key Trends:

Growing Demand for Plant-Based and Sustainable Sources:

Consumers are increasingly preferring plant-based and sustainable sources of collagen and gelatin, driven by ethical and environmental concerns. This has resulted in the creation of novel alternatives derived from seaweed, rice protein, and pea protein. Companies are investing in research to develop more efficient and environmentally friendly production processes to address the growing demand for plant-based alternatives in regenerative medical applications.

Increasing Use in Advanced Wound Care and Tissue Engineering:

Collagen and gelatin are increasingly being used in advanced wound care and tissue engineering due to their high biocompatibility, biodegradability, and ability to encourage cell development and tissue regeneration. Companies are investing in R&D to develop innovative collagen and gelatin-based solutions for wound healing, bone regeneration, and organ replacement. The increasing prevalence of chronic wounds, diabetes, and cancer is fueling the demand for these advanced regenerative medicine solutions.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Collagen and Gelatin Market for Regenerative Medicine Market Regional Analysis

Here is a more detailed regional analysis of the collagen and gelatin market for regenerative medicine market:

North America:

According to Verified Market Research, North America is estimated to dominate the collagen and gelatin market for regenerative medicine market over the forecast period. North America, particularly the United States, has a high prevalence of chronic diseases and injuries that could benefit from regenerative medicine treatments based on collagen and gelatin. According to the Centers for Disease Control and Prevention (CDC), six out of every ten persons in the United States have a chronic disease, with four out of ten having two or more. According to the CDC, approximately 54.4 million US individuals (or around 23%) have doctor-diagnosed arthritis, a condition for which collagen-based medicines show promise. The region's high disease load increases the demand for innovative regenerative medicine treatments.

Furthermore, North America is at the forefront of regenerative medicine research and development, which is driving the collagen and gelatin market. The California Institute for Regenerative Medicine (CIRM), the United States' largest state-funded stem cell agency, has committed more than USD 3 Billion in regenerative medicine research since its creation. In addition, the National Institutes of Health (NIH) reported funding for regenerative medicine research of around USD 2.5 Billion in fiscal year 2020. This large investment supports regional innovation and market growth.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The Asia Pacific region's aging population is rapidly growing, resulting in increased demand for regenerative medicine solutions. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the region's elder population (aged 65 and more) is predicted to more than double from 535 million in 2015 to around 1.3 billion by 2050. In East and North-East Asia, the population aged 65 and up is expected to grow from 260 million in 2020 to 573 million by 2050. This demographic shift increases the demand for collagen and gelatin-based regenerative medicines to address age-related health concerns.

Furthermore, the Asia Pacific region is experiencing an increase in chronic diseases, resulting in a significant market for regenerative medicine. According to the World Health Organization (WHO), non-communicable diseases (NCDs) account for 71% of all deaths worldwide, with a disproportionate impact on low- and middle-income nations, the majority of which are in Asia. According to the International Diabetes Federation (IDF), the number of adults with diabetes in Southeast Asia is anticipated to grow from 88 million in 2019 to 153 million by 2045. This increased illness load is encouraging the use of advanced regeneration treatments such as collagen and gelatin.

Europe:

Europe region is estimated to exhibit substantial growth within the market during the forecast period. Europe has one of the world's oldest populations, which fuels demand for regenerative medicine treatments. According to Eurostat, the proportion of adults 65 and older in the EU-27 is expected to rise from 20.3% in 2019 to 29.4% by 2050. This demographic transition coincides with an increase in age-related ailments. For example, the European League Against Rheumatism (EULAR) estimates that over 120 million people in the EU suffer from rheumatic and musculoskeletal illnesses (RMDs), many of which could benefit from collagen and gelatin-based regenerative therapies. The aging population and accompanying health challenges are driving the regenerative medicine market in Europe.

Furthermore, Europe is witnessing an increasing burden of chronic diseases, providing a sizable market for regenerative medicine treatments. Chronic diseases, according to the World Health Organization (WHO), account for 86% of fatalities and 77% of disease burden in Europe. The European Heart Network states that cardiovascular disease kills 3.9 million people in Europe each year, accounting for 45% of all deaths. Many of these chronic illnesses benefit from collagen and gelatin-based regenerative therapies, resulting in market expansion.

Collagen and Gelatin Market for Regenerative Medicine Market: Segmentation Analysis

The Global Collagen and Gelatin Market for Regenerative Medicine Market is segmented based on Source, Application, and Geography.

Collagen and Gelatin Market for Regenerative Medicine Market, By Source

• Bovine
• Porcine
• Marine
• Others

Based on Source, the Collagen and Gelatin Market for Regenerative Medicine Market is segmented into Bovine, Porcine, Marine, and Others. The bovine segment is estimated to dominate the collagen and gelatin market for regenerative medicine market due to the extensive use of bovine-derived collagen and gelatin, which are highly biocompatible and biodegradable. Because of the huge scale of cow ranching, bovine supplies are frequently less expensive, making them a preferred alternative for a variety of regenerative medicine applications such as wound care and orthopedic operations, resulting in market leadership.

Collagen and Gelatin Market for Regenerative Medicine Market, By Application

• Wound Care
• Orthopedic
• Cardiovascular
• Others

Based on Application, the Collagen and Gelatin Market for Regenerative Medicine Market is segmented into Wound Care, Orthopedic, Cardiovascular, and Others. The orthopedic segment is estimated to dominate the collagen and gelatin market for regenerative medicine market due to the increasing use of collagen and gelatin-based biomaterials in orthopedic procedures such as joint replacements and bone restoration. The rising prevalence of orthopedic disorders, combined with advances in surgical procedures and product improvements, has greatly increased demand for these materials, making orthopedics the market's largest application segment.

Collagen and Gelatin Market for Regenerative Medicine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the Collagen and Gelatin market for regenerative medicine market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is estimated to dominate the market during the forecasted period due to the high prevalence of chronic diseases, a well-developed healthcare infrastructure, and the existence of major market participants. The region's excellent research capabilities and major investments in regenerative medicine strengthen its position. Furthermore, the growing use of collagen-based products in a variety of medical applications, such as wound care and orthopedic procedures, helps North America maintain its market leadership.

Key Players

• The "Collagen and Gelatin Market for Regenerative Medicine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Integra Lifesciences Holdings Corporation, Collagen Matrix Inc., Collagen Solutions PLC, Royal DSM, VorniaBiomaterials Ltd., Symatese, Nucollagen LLC., Gelita AG, Nitta Gelatin, Inc., and PB Gelatin.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Collagen and Gelatin Market for Regenerative Medicine Market Recent Developments
• In January 2023, TELA Bio, Inc. developed the NIVIS Fibrillar Collagen Pack, an absorbent matrix composed of Type I and Type III bovine collagen. This product is intended to address moderately to heavily oozing wounds and minimal bleeding, and it represents a substantial contribution to the company's regenerative medicine portfolio. The launch demonstrates TELA Bio's dedication to providing improved wound care products.
• In October 2022, Collagen Matrix announced the acquisition of Polyganics B.V., to increase its range of bioresorbable products and technological platforms for bone and tissue restoration. This acquisition is expected to strengthen Collagen Matrix's regenerative medicine capabilities, allowing for the development of novel solutions to address the growing need for surgical applications.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET, BY SOURCE

• 5.1 Collagen Sources
  • 5.1.1 Bovine
  • 5.1.2 Porcine
  • 5.1.3 Marine
• 5.2 Gelatin Sources
  • 5.2.1 Bovine
  • 5.2.2 Porcine
  • 5.2.3 Others

6 GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET, BY APPLICATION

• 6.1 Collagen
  • 6.1.1 Orthopedic
  • 6.1.2 Wound Care
  • 6.1.3 Cardiovascular
  • 6.1.4 Others
• 6.2 Gelatin
  • 6.2.1 Wound Care
  • 6.2.2 Orthopedic
  • 6.2.3 Cardiovascular
  • 6.2.4 Others

7 GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East And Africa

8 GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Share
• 8.3 Vendor Landscape
• 8.4 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Integra Lifesciences Holdings Corporation
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Collagen Matrix, Inc.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Collagen Solutions PLC
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Royal DSM
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 VorniaBiomaterials Ltd.
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Symatese
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Nucollagen LLC.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Gelita AG
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Nitta Gelatin Inc.
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 PB Gelatin
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research